SK Biopharmaceuticals Posts Record Q1 Operating Profit of 89.8 Billion Won as Xcopri Continues US Growth
US Sales Reach 197.7 Billion Won; Record Number of New Prescriptions
Expanding Investment in RPT and TPD
"Entering a Virtuous Cycle Based on New Drug Cash Flow"
SK Biopharmaceuticals announced on May 7 that it recorded sales of 227.9 billion won and operating profit of 89.8 billion won in the first quarter of this year. Operating profit increased by 94% compared to the previous quarter and by approximately 250% year-on-year. Net profit for the period was tallied at 102.7 billion won.
The company’s performance was driven by the growth of cenobamate (marketed as Xcopri in the US), an epilepsy treatment, in the US market. US sales reached 197.7 billion won, marking a 48.4% increase from the same period last year.
Prescription indicators also expanded. In March, monthly total prescriptions (TRx) neared 47,000, while new-to-brand prescriptions (NBRx) surpassed 2,000 in a month for the first time. The company plans to expand both direct-to-consumer (DTC) advertising and marketing targeting medical professionals in the US, leveraging its direct sales framework.
SK Biopharmaceuticals is also working to broaden cenobamate’s indications. In March, the company submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for a suspension formulation and is working to apply for expanded indications for primary generalized tonic-clonic seizures (PGTC) and pediatric patients within this year.
The company is also expanding its presence in global markets. In China, it began commercialization in March this year through its partner, Ignis Therapeutics, and approval procedures are underway in Japan, with plans to complete them within the year.
SK Biopharmaceuticals plans to expand investment in next-generation pipelines, including radiopharmaceutical therapeutics (RPT) and targeted protein degradation (TPD), using the cash flow generated from cenobamate sales.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from SK Biopharmaceuticals said, "Based on a profit structure centered on new drug sales, we are simultaneously pursuing investment in new pipelines and profit growth."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.